Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GRN | P28799 | 1/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537472 | 0.80 | HDAC3 (0.41) | KDM4EGRNSORT1LMNA | |
| SCHEMBL19274376 | 0.77 | GRN (0.41) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL16946322 | 0.77 | KDM4E (0.34) | KDM4EGRNSORT1 | |
| SCHEMBL25908750 | 0.77 | KDM4E (0.34) | KDM4EGRNSORT1 | |
| SCHEMBL8932305 | 0.77 | KDM4E (0.34) | KDM4EGRNSORT1 | |
| SCHEMBL21305805 | 0.76 | GRN (0.40) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL422069 | 0.74 | KDM4E (0.52) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL821308 | 0.74 | KDM4E (0.52) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL19508071 | 0.74 | KDM4E (0.52) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL23402437 | 0.74 | CNR1 (0.44) | KDM4EGRNSORT1MAPK14MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202003-A1 | POLYMERISATION INHIBITORS | BASF SE (DE) | 2025-10-02 | — | — | WO | disclosed |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3828159-A1 | STORAGE AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2021-06-02 | — | — | EP | disclosed |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2021-02-09 | — | — | US | disclosed |
| US-10391077-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2019-08-27 | — | — | US | disclosed |
| US-10329310-B2 | Arginase inhibitors and their therapeutic applications | ONCO ARENDI THERAPEUTICS S.A. (PL) | 2019-06-25 | — | — | US | disclosed |
| EP-2079806-B1 | TRISAZO-DYES WITH A PYRAZOLYL END GROUP AND THEIR USE IN INK-JET PRINTING | FUJIFILM IMAGING COLORANTS LTD (GB) | 2011-07-06 | — | — | EP | disclosed |
| US-7704310-B2 | Trisazo-dyes with a pyrazolyl end group and their use in ink-jet printing | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-7704310-B2 | Trisazo-dyes with a pyrazolyl end group and their use in ink-jet printing | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-20100015411-A1 | Trisazo-dyes with a Pyrazolyl End Group and Their Use in Ink-jet Printing | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100015411-A1 | Trisazo-dyes with a Pyrazolyl End Group and Their Use in Ink-jet Printing | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2008047071-A1 | TRISAZO-DYES WITH A PYRAZOLYL END GROUP AND THEIR USE IN INK-JET PRINTING | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| EP-1480973-B1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-02-13 | — | — | EP | disclosed |
| US-5536701-A | 3-pyrazolyloxypyridazines, herbicidal compositions and uses thereof | MONSANTO COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
| US-4163052-A | NEMATOCIDES, FUNGICIDES, ARTHROPODICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1979-07-31 | — | — | US | disclosed |
| US-4146632-A | NEMATOCIDES, ARTHROPODICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391077-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | KDM4E 2969/4885GRN 2340/4885SORT1 3886/4885 |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KDM4E 734/4885GRN 2303/4885SORT1 4769/4885 |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KDM4E 734/4885GRN 2303/4885SORT1 4769/4885 |
| US-10329310-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, PRMT1 | KDM4E 1748/4885GRN 2202/4885SORT1 1803/4885 |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | LIPG, FABP2, EPCAM | KDM4E 4414/4885GRN 1114/4885SORT1 1753/4885 |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | KDM4E 2969/4885GRN 2340/4885SORT1 3886/4885 |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | SNCA, NGF, SLC18A2 | KDM4E 1151/4885GRN 16/4885SORT1 1128/4885 |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | KDM4E 4426/4885GRN 678/4885SORT1 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.